Huw Davies

We're pleased to share that Cellular Origins (a TTP company), Cell and Gene Therapy Catapult (CGT Catapult), and Resolution Therapeutics have announced the formation of a new consortium focused on transforming #CellTherapyManufacturing. ➡️ https://lnkd.in/eF_E9-VM The consortium has been awarded a £1 million Smart Grant from Innovate UK to develop a globally unique, fully automated, and scalable platform for cell therapy production. The project began on 1 July 2025 and will run for 20 months. Continue reading in the reading above ⤴️

149

4 Comments

Coulter Partners successfully completed a search assignment for NeoPhore Ltd and is pleased to announce the placement of Michael Shih, as Chief Executive Officer. NeoPhore, a small molecule neoantigen immuno-oncology company, is developing a pipeline of highly validated, first-in-class small molecule drugs targeting proteins across the DNA mismatch repair (MMR) pathway to improve the efficacy and durability of revolutionary immunotherapies to treat cancer. Read the full press release here:  https://lnkd.in/dZgcEHhG #lifesciences #leadership #executivesearch #toptalent Key players for this placement: Chris Palatucci, Clare Evans-Argent, Gabrielle (Gabby) Banzon, Kay Wardle, and Ruby Charteris.

91

The current drug development process can be long, complex, and resource intense. In this guide, uncover how Oxford Nanopore technology is transforming the biopharma development pipeline with a single platform that streamlines the process from discovery to clinical development. Read here: https://lnkd.in/eCn9j2RB

56

1 Comment

💡 Strong data science tools are essential for making informed decisions in drug development. Dr. Allan Jordan from Sygnature Discovery sits down with Lauren Brown and Alister Campbell from Dotmatics to discuss the future of data driven research in oncology and drug discovery. 🔗 https://lnkd.in/eNmcv4t9

55

𝗡𝗮𝗻𝗼𝗩𝗮𝘁𝗶𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗼𝗻 𝗕𝗶𝗼𝗧𝗲𝗰𝗵 𝗧𝗩 Two of our co-founders, Pieter Cullis and Jayesh Kulkarni, discuss the challenge of successfully using lipid nanoparticles (#LNPs) to deliver payloads beyond the liver—one of the key frontiers in drug delivery. A big thank you to BiotechTV for highlighting our work and perspective on this critical research focus, which has been at the heart of NanoVation Therapeutics since its inception. 🎥 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝗵𝗲𝗿𝗲: https://lnkd.in/gbeSwZG9 #NanoVationTherapeutics #Biotech #LipidNanoparticles #DrugDelivery #Innovation #BioTechTV #NucleicAcids #GeneticMedicine

142

1 Comment

Exciting research at #AACR2025!   Explore our collaborative poster #178 with Propath UK and Bruker Spatial Biology on using automated AI-based spatial profiling to understand the role of hypoxia in head and neck cancer.   Leveraging Visiopharm's Oncotopix Discovery and GeoMx DSP, the team developed a high-throughput workflow that automates ROI and AOI selection, minimizing bias and enhancing accuracy in studying tumor microenvironments.   This innovative approach brings new insights into immune infiltration patterns and hypoxia gradients, helping to pave the way for more targeted therapies.   👉 Don’t miss poster #178 today from 2PM-5PM if you are at AACR!   Authors: Kelly Hunter , Joana Campos , Jack L. McMurray, Melanie Weigand, Chris Morse, Ketaki Hardikar, Regan Baird, David Mason, Kyla Teplitz, Hisham Mehanna, Jill Brooks

39

Combining proteomics with high-resolution imaging data could be a game-changer in our deeper understanding of disease biology. The UK Biobank Pharma Proteomics Project (UKB-PPP) recently announced the largest proteomics study in history, where they intend to measure over 5,400 proteins in 600,000 samples using Olink® Explore HT. In the clip below, Dr. Whelan describes how the study design of the new phase of the UKB-PPP will provide a new level of granularity in the biological insights obtained, linking not only proteins to disease but also to organ structural changes that are critical to the pathophysiology involved. Watch full version of the Episode 23 of the Proteomics in Proximity podcast (https://hubs.la/Q034spzt0), where Professor Sir Rory Collins (Principal Investigator UK Biobank & University of Oxford) and Dr Chris Whelan (Director, Johnson & Johnson Innovative Medicine) discuss this momentous project and its implications for the development of precision medicine and the future of human healthcare.

43

Antibody-drug conjugates (ADCs) offer a potentially revolutionary advance in targeted cancer therapy as they combine antibodies and potent cytotoxic payloads to deliver drugs straight into cancer cells. Our latest blog post explores the critical role organoids play in ADC development, highlighting recent advances and examining the strengths and limitations compared to other models. Organoids are invaluable tools, supporting rapidly expanding ADC development and unlocking new personalized therapies. Learn more in our blog post ➡️ https://hubs.la/Q031HVPr0

35

1 Comment